Carolyn Taylor Acquires 1,415 Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) Stock

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Director Carolyn Taylor acquired 1,415 shares of the stock in a transaction on Friday, June 12th. The shares were bought at an average price of $10.55 per share, for a total transaction of $14,928.25. Following the purchase, the director owned 1,833 shares in the company, valued at approximately $19,338.15. This trade represents a 338.52% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.

Tonix Pharmaceuticals Trading Up 1.0%

NASDAQ TNXP opened at $11.63 on Wednesday. Tonix Pharmaceuticals Holding Corp. has a 1 year low of $10.03 and a 1 year high of $69.97. The firm’s 50 day simple moving average is $12.95 and its 200 day simple moving average is $14.89. The firm has a market capitalization of $185.38 million, a price-to-earnings ratio of -0.81 and a beta of 1.67.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings results on Monday, May 11th. The company reported ($2.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.54) by ($0.39). Tonix Pharmaceuticals had a negative net margin of 839.52% and a negative return on equity of 67.65%. The business had revenue of $6.88 million during the quarter, compared to the consensus estimate of $6.13 million. On average, equities research analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -9.94 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research note on Monday, April 20th. Wall Street Zen lowered Tonix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, April 26th. Finally, TD Cowen upgraded Tonix Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, May 5th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $22.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc acquired a new position in Tonix Pharmaceuticals during the 2nd quarter worth about $25,000. Strs Ohio lifted its stake in shares of Tonix Pharmaceuticals by 9.9% in the 4th quarter. Strs Ohio now owns 7,800 shares of the company’s stock valued at $122,000 after purchasing an additional 700 shares during the period. Rhumbline Advisers lifted its stake in shares of Tonix Pharmaceuticals by 8.0% in the 3rd quarter. Rhumbline Advisers now owns 12,206 shares of the company’s stock valued at $295,000 after purchasing an additional 908 shares during the period. Bank of America Corp DE lifted its stake in shares of Tonix Pharmaceuticals by 32.7% in the 3rd quarter. Bank of America Corp DE now owns 4,651 shares of the company’s stock valued at $112,000 after purchasing an additional 1,146 shares during the period. Finally, Russell Investments Group Ltd. acquired a new position in shares of Tonix Pharmaceuticals in the 3rd quarter valued at about $29,000. 82.26% of the stock is owned by institutional investors and hedge funds.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.